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Trimeric soluble forms of HIV gp140 envelope glycoproteins represent one of the closest molecular structures
compared to native spikes present on intact virus particles. Trimeric soluble gp140 have been generated by several
groups and such molecules have been shown to induce antibodies with neutralizing activity against homologous
and heterologous viruses. In the present study, we generated a recombinant trimeric soluble gp140, derived from a
previously identified Ugandan A-clade HIV field isolate (gp14094UG018). Antibodies elicited in immunized rabbits
show a broad binding pattern to HIV envelopes of different clades. An epitope mapping analysis reveals that, on
average, the binding is mostly focused on the C1, C2, V3, V5 and C5 regions. Immune sera show neutralization
activity to Tier 1 isolates of different clades, demonstrating cross clade neutralizing activity which needs to be
further broadened by possible structural modifications of the clade A gp14094UG018. Our results provide a rationale
for the design and evaluation of immunogens and the clade A gp14094UG018 shows promising characteristics for
potential involvement in an effective HIV vaccine with broad activity.Introduction
Major challenges in the development of an HIV vaccine
have been the design of immunogens able to induce a
strong and sustained immunity with a broad and cross-
clade neutralizing activity.
In the course of natural infection, although HIV-1 is
highly effective in evading the immune surveillance
[1-3], almost 20% of HIV-infected subjects are able to
develop antibodies with a broad degree of neutralization
activity, whose role in the disease control, however, is
still debated (reviewed in [4]. Such evidences, indeed,
suggest that native antigens are able to elicit such bnAbs
antibodies. To date, a number of human bnAbs targeting
the HIV envelope glycoprotein in its trimeric status have
been isolated from HIV-1 infected subjects [5-14].* Correspondence: l.buonaguro@istitutotumori.na.it
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reproduction in any medium, provided the orTrimeric envelope structures, either soluble or pro-
truding from a membrane-surrounded particle, have
been explored as vaccine models for eliciting broadly
neutralizing antibodies (bnAbs) [15-19].
Indeed, the native and functional HIV-1 envelope
glycoprotein (Env) complex is present on the virus sur-
face as a trimer, each of the monomers made of non-
covalently loosely associated gp120 surface and gp41
transmembrane glycoproteins [20-23]. However, recom-
binant soluble forms of fully cleaved and functional
trimers, have been difficult to obtain for their high in-
stability. On the other hand, the use of gp160
ectodomain (gp140) has led to the production of trimers
that can mimic the native Env spike and have shown to
be able to elicit neutralizing antibody responses in im-
munized animals [24-27]. These gp140 trimers can be
further stabilized by introduction of specific modifica-
tion in order to strenghten intra- as well as inter-
molecular bindings (gp140SOSIP) [28,29].
We have recently used a similar strategy to present tri-
meric gp140 Env molecules on HIV Virus-Like Particlesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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system [19] and a stably transfected insect cell line [18].
In particular, a gp120 Env molecule derived from a
Ugandan HIV-1 isolate of the clade A (94UG018;
GenBank accession number AF062521) [30,31] has pre-
viously been shown to induce high Ab titers with cross-
clade neutralizing activity in immunized BALB/C mice
[32-34] and non-human primates [35].
In the present study, the same gp14094UG018 presented
on the surface of VLPs has been produced as recombin-
ant soluble trimeric form of Env for evaluation in
homologous prime-boost immunization schedules. An
immunogenicity study has been performed in rabbits to
evaluate the potency and broadness of specific humoral
immune response as well as the mapping of the epitope
recognition by the Abs elicited by such protein.
Material and methods
Protein immunogen
Recombinant gp140 protein was produced by transient
transfection of the pLex-gp14094UG018 plasmid into ad-
herent 293T cells grown in DMEM media supplemented
with 10% FCS. Supernatants were collected after 48
hours and fresh media, containing 10% FCS was added
to the cells for another 48 hours at which time point the
media was collected again. Following centrifugation and
filtration of the supernatant through a 0.22 μm filter, the
protein was isolated from the pooled supernatants by
initial capture using Talon IMAC chromatography, and
elution with TBS with 250 mM imidazole followed by
GNL Lectin (Vector Labs) capture and eluted with 1M
methyl α-D mannopyranoside, 100 mM sodium acetate
(pH 4.0) and finally gel filtration with a SD200 column
equilibrated with PBS. The protein production and puri-
fication was performed using endotoxin-free materials
and buffers. The protein was concentrated using a 10
kDa molecular weight cutoff protein concentrator to
1 mg/ml in PBS for immunization.
Immunization protocol
Four female New Zealand white rabbits 6 to 8 weeks old
(with a body weight of ~2 kg), were subcutaneously im-
munized with the trimeric Clade A gp14094UG018 in the
presence of the adjuvant CAF01 [36]. Immunizations
were performed at week 0, 2, 4 and 8 and each rabbit
received 100μg/dose of immunogen. Blood was collected
3 days before the immunization protocol started (pre-
immunization) and four (week 12) and six (week 14)
weeks after the last immunization. Heat inactivated sera
were stored at −80°C until used. All animal handlers
were certified in laboratory animal science courses
complying with the category B or C requirements of the
Federation of European Laboratory Animal Science
Association (FELASA). Animal experiments wereperformed according to the Animal Experimentation
Act of Denmark and European Convention ETS 123
(Protection of Vertebrate Animals used for experimental
and other scientific purposes).
ELISA assays
Measurement of specific anti-HIV Env IgG antibodies in
rabbit serum
The level of anti-envelope specific IgG antibodies in sera
of immunized rabbits was determined by ELISA. Five
antigens were used: gp14094UG018 (Clade A), gp120 IIIB
(Clade B), gp120 W61D (Clade B), gp140 ZM96 (Clade C)
or gp140 UG037 (Clade A). Briefly, 100 or 200 μL of each
antigen at a final concentration of 1 μg/mL in PBS were
directly coated on 96-well MICROTEST assay plates
(Becton Dickinson) and plates were incubated overnight
at 4°C. Five-fold dilutions (starting from 1:1000) of each
rabbit serum were added to the wells and incubated 2
hrs at 37°C. After washing, 100 μL of goat anti-rabbit
IgG horseradish peroxidase (HRP)-conjugated was added
to each well at a concentration of 1 μg/mL. A TMB
Ultra 1-step solution (Thermo Scientific) was used to
develop the reactions which were stopped after 30 mi-
nutes with 100 μl/well of 2N H2SO4. Plates were read at
450 nm. Reactions were considered positive when the
optical density (OD) measured by the ELISA was higher
than the O.D. + 3SD of the same dilution of pre-
immunization sera.
B-cell epitope mapping
B-cell epitope mapping was carried out using 20 mer
overlapping synthetic peptides spanning the entire
length of IIIB gp120 from C1 to C5 region. For each re-
gion 20 mer overlapping synthetic peptides were pooled
or singularly coated at a final concentration of 1 μg/ml
per each peptide directly on 96-well MICROTEST assay
plates (Becton Dickinson) which were incubated over-
night at 4°C. Each rabbit serum was added at a dilution
of 1:1000 and incubated 2 hrs at 37°C against pools or
single peptides. Each tested pool covered a region of
gp120. Goat anti-rabbit IgG HRP-conjugated was added
to each well at a concentration of 1 μg/mL and the same
procedure as indicated above was followed.
Neutralization assay
IgG were purified from heat inactivated (1 hr 56°C)
serum using Protein G HP SpinTrap columns (GE
Healthcare) according to the manufacturer’s instructions.
Eluted IgG fractions were quantified spectrophotomet-
rically (Nanodrop). Neutralizing activity of IgG from im-
mune rabbit sera was evaluated against primary isolates
(Bx08, SF162, QH0692, MW965, 92BR025, DJ263.8,
92RW009) through the TZM-bl assay [37]. Briefly, 200
TCID50 of pseudovirus was incubated with four 2-fold
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at 37°C in a total volume of 100 μl growth medium in
96-well flat-bottom culture plates. Freshly trypsinized
cells (1 × 104) were then added in 10% DMEM growth
medium containing DEAE-dextran (Sigma) at a final
concentration of 15 μg/ml. After 48 h incubation, 100 μl
of growth medium was removed from each well and 100
μl of SteadyLite reagent (Perkin Elmer) was added.
Luminescence was measured using a Berthold TriStar
LB941 luminometer (PerkinElmer). The background
controls contained cells only, while the virus controls
contained cells plus virus. The percent neutralization for
immune rabbit IgG was calculated comparing it to the
virus controls. The 50% inhibitory dose (IC50) was cal-
culated as the IgG concentration that induced a 50%
reduction in RLU compared to the virus control wells,
after subtraction of cell control RLU. Pre-bleed sera
were used as negative controls. TriMab, a mix of 3
mAbs (b12, 2G12 and 2F5), (obtained from Centre for
AIDS Reagents, NIBSC, UK) was used in every
neutralization experiment as a strongly neutralizing
control IgG.Results
Production of soluble trimeric gp14094UG018
The recombinant gp140 protein was expressed at ap-
proximately 0.5 mg/liter of DMEM media from transi-
ently transfected 293T cells, and protein expression was
expanded to approximately 10 litres. Following a size-
exclusion chromatography, fractions corresponding to
the gp140 trimer were collected and pooled. Protein
purity was analysed by SDS PAGE and shown to be
>95% following the final size-exclusion step (Figure 1).Figure 1 Analysis of the gp14094UG018 protein. (A) The trimeric form of r
chromatography. (B) Fractions corresponding to the gp140 trimer were poole
the purity of the product.Induction of anti-gp140 specific antibodies
Induction of a humoral immune response by soluble
trimeric Clade A gp14094UG018 was evaluated in sera by
ELISA performed on microwell plates coated with the
monomeric form of the protein used for immunization
protocol. Pre-immunization, week 12 and week 14 sera
were tested and specific anti-gp140 antibodies were
identified in sera from immunized rabbits, with a
response stronger at week 12 than at week 14 (Figure 2).
Indeed, all four sera from immunized animals at week
12 show a binding to the gp14094UG018, at the 1:625,000 di-
lution, statistically significant higher than pre-immunized
sera (week 0) (p < 0.01). On the contrary, at the same
serum dilution, only one (Rb 49381) of the immunized
sera at week 14 show a binding statistically significant
higher than pre-immunized sera (week 0) (p < 0.05). More-
over, a 50% of maximal binding activity was obtained, on
average, with a 1:2.25 × 105 dilution of week 12 serum and
a 1:6.5 × 104 dilution of the week 14 serum (p < 0.01), indi-
cating the elicitation of a strong anti-gp140 antibody
response four to six weeks after last immunization. Pre-
immunization sera showed no positive reactions at any of
the dilutions tested.Determination of broadness of humoral immune
response to Env
In order to evaluate the broadness of the binding charac-
terizing the sera from animals immunized with the tri-
meric gp14094UG018, pre-immune (week 0) and immune
sera (week 12) were tested in ELISA against the recom-
binant HIV gp120/gp140 proteins of different clades, i.e.
IIIB (Clade B), W61D (Clade B), ZM96 (Clade C) and
UG037 (Clade A). These proteins show, along the entireecombinant gp140 protein was verified and purified by a size-exclusion
d and analyzed by Coomassie stained denaturing SDS PAGE to confirm
Figure 2 Evaluation of IgG titers elicited in sera of immunized
rabbits against the homologous trimeric gp14094UG018. Five-fold
dilutions of heat inactivated sera from pre-immunized (week 0) and
immunized rabbits (week 12 and 14) were evaluated in ELISA for
their reactivity with homologous gp140. Week 12 and 14 correspond
to 4 and 6 weeks after the last antigen administration. The 50%
binding is indicated for the week 12 and 14 sera.
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glycoprotein in particular in the constant regions
(i.e. C1, C2 and C5) and significantly lower in the variable
regions (Figure 3). This is observed also for the UG037,
which is of the same clade (Figure 3).
Sera from all immunized animals showed a high anti-
body titer at week 12 against all tested proteins, with a
ranking of UG037 = ZM96 >W61D > IIIB (p < 0.01)
(Figure 4). In particular, results show that 50% binding
activity was obtained, on average, with a 1:2.25 × 105
dilution for the UG037 and ZM96 proteins, exactly the
same as for the homologous 94UG018 protein (Figure 2),
a 1:1.25 × 105 dilution for the W61D protein and a 1:4.5 ×
104 dilution for the IIIB protein (Figure 4). The ELISA re-
sults clearly show that immunization with the trimeric
gp14094UG018 induces an immune response with a broad
binding activity, recognizing HIV gp120 molecules from
different clades.
Evaluation of envelope epitopes recognized by the
immune sera
In order to identify the main gp120 epitopes recognized by
the immune sera elicited by the trimeric gp14094UG018,
epitope mapping was carried out using 20 mer overlapping
synthetic peptides spanning the entire length of gp120 from
the C1 to the C5 region. A tiled array of 47 syntheticpeptides (20 aa each) overlapping by 10 residues covering
the entire length of gp120 (Table 1) was used for epitope
mapping. The heatmap is derived on the O.D.450 values
obtained at ELISA reacting sera from each animal to pep-
tides: the higher is the O.D. value (e.g. higher affinity) the
darker is the color in the heatmap. Results, showed that the
12 week sera from all immunized animals bound the C1,
C2 and C5 constant regions with high affinity and the V2,
V3 and V5 variable regions with lower affinity (Figure 5A).
The remaining C3 and C4 constant regions as well as the
V1 and V4 variable regions were bound with limited affinity
or not bound at all. These results strongly correlated with
the percentage of divergence between the sequence of the
gp14094UG018 and the peptides used as targets in the ELISA
(Figure 5B). Nevertheless, it is relevant to note that the im-
munized animals showed a significant breadth of binding
to the target epitopes, suggesting that the same vaccine
molecule is able to elicit distinct patterns of antibodies
focusing on different epitopes.
Within the overlapping peptide pools with the highest
binding responses, individual overlapping peptides were
used as targets for ELISA using sera collected at week
12 (Table 2). The heatmap built on the O.D.450 values
shows that, for each rabbit serum, reactivity against indi-
vidual peptides was not homogeneous, indicating that
the reactivity observed against the pools were attribut-
able to specific epitopes (Figure 6). Moreover, most pep-
tides were recognized by each rabbit serum with a broad
range of binding efficiency, suggesting that specific re-
gions of the gp14094UG018 have different potency in
eliciting an immune response in the evaluated animals
(Figure 5 and Table 2) [38]. The regions best bound by
antibodies from immunized sera are depicted in an
X-ray conformational structure of gp120 (Additional file 1:
Figure S1).Breadth of neutralizing antibodies (NAbs) elicited by
vaccination with recombinant trimeric gp14094UG018
Induction of Nabs in rabbits immunized with recombin-
ant trimeric gp14094UG018 was evaluated in the TZM-bl
neutralization assay against a panel of 7 HIV-1 isolates
using IgG purified from sera collected at week 0, 12 and
14 (T0, T12 and T14 respectively). In particular, 3 viruses
were clade B isolates (Bx08, SF162 and QH0692), 2 were
clade C viruses (MW965 and 92BR025), 1 virus belonged
to the 02_AG subtype (DJ263.8) and 1 virus was a clade
A and C mosaic isolate (92RW009). The virus isolates
MW965, 92Br025, DJ263.8, Bx08 and SF162 are known
to be Tier 1 while the virus isolate 92RW009 and
QH0692 are classified as Tier 2 isolates. A heatmap was
generated based upon the 50% neutralization effect,
indicating in red the neutralization results above 50% for
each IgG concentration (Figure 7A).
Figure 3 Analysis of sequence homology. The gp120 amino acid sequence of the indicated HIV isolates were aligned with the 94UG018 clade
A Ugandan isolate. Sequence homology between each isolate vs the 94UG018 isolate is indicated along the whole gp120 sequence.
Figure 4 Evaluation of IgG titers elicited in sera of immunized rabbits against heterologous HIV gp120. Five-fold dilutions of heat
inactivated rabbits sera, collected at 4 weeks after the last antigen administration (week 12), were evaluated in ELISA for their reactivity with
heterologous gp120s. The 50% binding is indicated.
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Table 1 Inhibitory concentration (IC) 50 for each animal to each viral isolate evaluated in the study
Virus Week 12 Week 14
49378 49381 49384 49391 49378 49381 49384 49391
SF162 62.5 31.25 62.5 31.25 125 125 125 125
BX08 62.5 62.5 125 31.25 250 62.5 >250 >250
MW965 62.5 62.5 62.5 31.25 125 125 125 31.25
DJ263.8 >250 >250 >250 125 250 >250 >250 250
92Br025 >250 >250 >250 >250 >250 >250 >250 >250
92RW009 >250 >250 >250 >250 >250 >250 >250 >250
QH0692 >250 >250 >250 >250 >250 >250 >250 >250
Values are expressed in μg/ml of IgG and represent the reciprocal dilutions.
Figure 5 Heatmap of binding to gp120 peptides’ pool. (A) Intensity of serum binding in ELISA to peptides’ pool covering the constant and
variable regions of gp120 is shown as heatmap. Increasing O.D. value, indicating stronger binding, is represented as darker color. (B) Sequence
divergence between peptides used as target in ELISA and the 94UG018 clade A Ugandan isolate is indicated along the whole gp120 sequence.
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Table 2 Overlapping peptides from HIVIIIB used to fine mapping the binding of rabbit sera elicited by the trimeric
gp140Uganda
Gp120 region Peptide code Sequence Gp120 region Peptide code Sequence
C1
ARP740-1 ATEKLWVTVYYGVPVWKEATTT
C2
ARP740-24 NGSLAEEEVVIRSVNFTDNA
ARP740-2 VPVWKEATTTLFCASDAKAY ARP740-25 IRSVNFTDNAKTIIVQLNTS
ARP740-3 LFCASDAKAYDTEVHNVWAT ARP740-26 VQLNTSVEINCTR
ARP740-4 DTEVHNVWATHACVPTDPN
V3
ARP740-27 VEINCTRPNNNTRKRIRIQ
ARP740-5 HACVPTDPNPQEVVLVNVTE ARP740-28 NTRKRIRIQRGPGRAFVTIG
ARP740-6 PQEVVLVNVTENFDMWKNDMV ARP740-29 RGPGRAFVTIGKIGNMRQA
ARP740-7 NFDMWKNDMVEQMHEDIISL ARP740-30 KIGNMRQAHCNISRAKWNNT
ARP740-8 EQMHEDIISLWDQSLKPCVK
C3
ARP740-31 HCNISRAKWNNTLKQIDSKL
ARP740-9 WDQSLKPCVKLTPLCVSLK ARP740-32 LKQIDSKLREQFGNNKTIIF
V1
ARP740-10 LTPLCVSLKCTDLKNDTNTN ARP740-33 REQFGNNKTIIFKQSSGGDPE
ARP740-11 CTDLKNDTNTNSSSGRMIMEK ARP740-34 KQSSGGDPEIVTHSFNCGGE
ARP740-12 SSSGRMIMEKGEIKNCSFNI
V4
ARP740-35/36 GEFFYCNSTQLFNS
V2
ARP740-13 GEIKNCSFNISTSIRGKVQK ARP740-37 NSTWFNSTWSTEGSNNTEGS
ARP740-14 STSIRGKVQKEYAFFYKLDI ARP740-38 TEGSNNTEGSDTTTLPCRI
ARP740-15 EYAFFYKLDIIPIDNDTTSY
C4
ARP740-39 DTTTLPCRIKQIINMWQKVG
ARP740-16 IPIDNDTTSYSLTSCNTSVI ARP740-40 KQIINMWQKVGKAMYAPPIS
C2
ARP740-17 SLTSCNTSVITQACPKVSFE
V5
ARP740-41 KAMYAPPISGQIRCSSNITG
ARP740-18 TQACPKVSFEPIPHYCAPA ARP740-42 GQIRCSSNITGLLLTRDGGNS
ARP740-19 PIPHYCAPAGFAILKCNNK ARP740-43 LLLTRDGGNSNNESEIFRLG
ARP740-20 GFAILKCNNKTFNGTGPCNT
C5
ARP740-44 NNESEIFRLGGGDMRDNWRS
ARP740-21 TFNGTGPCNTVSTVQCTHGI ARP740-45 GGDMRDNWRSELYKYKVVKI
ARP740-22 VSTVQCTHGIRPVVSTQLLL ARP740-46 ELYKYKVVKIEPLGVAPTKA
ARP740-23 RPVVSTQLLLNGSLAEEEVV ARP740-47 EPLGVAPTKAKRRVVQREKR
Bold characters indicate the peptide with the strongest binding by immune sera.
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able to mainly neutralize tier 1 viruses across clades and
that this neutralization potency waned over time.
Considering the T12 sera, 3 of the 5 Tier 1 virus isolates
(SF162, Bx08 and MW965) were neutralized with an
IC50 of 62.5 μg/ml by all sera and with an IC50 of 31.25
μg/ml by serum from the 49391 rabbit. The latter serum
showed a neutralization activity also against DJ263.8
with an IC50 of 125 μg/ml (Figure 7A and Table 1), while
no neutralization against 92Br025 could be detected.
Tier 2 viruses were poorly or not neutralized in all cases.
Comparing the breadth and potency of neutralization,
it is noteworthy that the best performing serum (49391)
showed the strongest binding to the constant regions
(p <0.05) and the lowest binding to the variable regions
(V2 and V3) (p < 0.001), compared to the other sera. On
the contrary, the least performing sera (49378 and
49384) show a significant binding to the constant
regions, but the strongest binding to the V2 and V3
variable regions (p < 0.01) (Figure 7B).Discussion
In this study we evaluated the immunogenicity of a soluble
trimeric gp14094UG018 derived from a clade A HIV-1 isolate
administrated subcutaneously to rabbits. All four immu-
nized animals developed high titers of specific anti-gp140
antibodies against the homologous gp14094UG018 protein,
as well as against heterologous envelope glycoproteins of
clade B (gp120IIIB and gp120W61D), clade A (gp140UG037)
and clade C (gp140ZM96) which present a significant se-
quence divergence compared to the gp14094UG018. The
highest binding activity was observed against the two
gp140 UG037 and ZM96 molecules, effect that could be
due to the highest sequence homology to the gp140
94UG018 molecule (UG037) and/or the presence of the
ectodomain of gp41 which is substantially conserved
across the clades (UG037 and ZM96). Overall, these re-
sults indicate that although rabbits were immunized with
a clade A derived gp140, this immunization was able to
elicit a binding activity to cross-clade Env antigens. This
result was supported by the relevant sequence homology
Figure 6 Heatmap of binding to individual gp120 peptides. Intensity of serum binding in ELISA to each overlapping peptide covering the
indicated regions of gp120 is shown as heatmap. In each panel stronger binding is represented as darker color.
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stant regions.
All immunized animals’ sera were able to bind the C1,
C2 and C5 regions with high affinity and the V2, V3 and
V5 regions with lower affinity, presenting a direct correl-
ation with the percentage of divergence between the
gp14094UG018 immunogen and the peptides used as tar-
get in the binding assay. However, the differential
binding efficacy to the same peptide by different sera is
highly suggestive of distinct patterns of immune re-
sponse elicited by the same gp14094UG018 in outbred
animals, indicating that the specificity of individual re-
sponses to the same vaccine antigen is not totally pre-
dictable. A more in-depth epitope mapping analysis
performed with individual epitopes covering the entire
length of gp120 from the C1 to the C5 region confirmed
the potency ranking observed with the peptide pools but
showed that, for each region, specific peptides are recog-
nized more efficiently than others. This further supports
the concept that the immunogen is able to elicit distinct
patterns of Abs focused on different epitopes. Furtheranalysis have been planned to be conducted using pep-
tides based on the sequence of 94UG018 protein, to
verify whether additional Ab specificities are identified
in immune sera elicited by the gp14094UG018.
Sera from animals immunized with gp14094UG018
showed a >50% neutralization efficacy against 3 out of 5
Tier 1 pseudoviruses, whereas poor or no neutralization
was observed against Tier 2 pseudoviruses.
This soluble trimeric clade A gp14094UG018 was able to
induce a cross-clade neutralizing activity as demon-
strated by the ability of the immune sera to neutralize
Tier 1 pseudoviruses of different clades. Although
the neutralization activity was limited to Tier 1
pseudoviruses, this result is in agreement with other im-
munogenicity studies performed with soluble HIV Enve-
lope proteins of different clades with our data even
suggesting improved neutralization in several instances
[39-42]. Moreover, it is prospected to re-evaluate the
breadth of neutralization activity in A3R5 cells, which
have been recently shown to be more sensitive to
neutralization than the TZM-bl used in the present
Figure 7 Neutralization activity of sera from immunized rabbits. (A) Neutralization activity in TZM-bl cells obtained with serial dilutions of
IgG (expressed as μg/ml) purified from immunized sera is shown as heatmap for each virus tested. Neutralization activity >50% and <50% is
indicated in red and orange, respectively, whereas absence of neutralization activity is indicated in grey. Pre-bleed sera showed a negligible
neutralization activity (<10%). (B) Correlation matrix between neutralization activity and peptide binding to envelope gp120 regions. (C)
Neutralization activity of TriMab.
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was the only one to show neutralization activity against
four out of five Tier 1 with the highest activity and also
to show very limited neutralization activity, although
lower than the 50% threshold, against two of the Tier 2
pseudoviruses. This broader neutralization activity does
not seem to be attributable to antibodies to the V3
domain, as serum from the 49391 rabbit, compared to
the other sera, presents the weakest binding efficacy to
V3 epitopes, considered both as pool or individual pep-
tides. This observation is in contrast to previously reported
data showing that broadly neutralizing activity, in sera from
animals immunized with trimeric Clade A envelope mole-
cules, is mostly associated to antibodies directed toward the
envelope variable regions (V1, V2, V3) [44]. Interestingly,
our gp14094UG018 seems to divert the immune response
from variable region of envelope molecules. Further
analyses will need to be performed since these results could
be due to the high sequence divergence between the
gp14094UG018 and the gp120IIIB peptides used in our assay.Of note, all four immunized sera are characterized by
a stronger binding efficacy to epitopes of the constant
and V5 regions, which are known to be involved in the
CD4bs of the HIV gp120 and are targets of few broadly
cross-clade neutralizing monoclonal antibodies (bnAbs)
[11,45,46]. The poor or absent binding to C3 epitopes is
most likely due to the extremely high divergence (>60%)
of the C3 region sequence in the gp14094UG018 which
may severely affect the Ab-epitope recognition. Never-
theless, the strong binding to epitopes covering regions
involved in the CD4bs may possibly suggest that such
antibodies may play a relevant role in the neutralization
activity of immunized sera, although the broadness of
their activity is confined only to Tier 1 isolates. Indeed,
the observed strong binding to C1 epitopes may possibly
play a role in the insufficient pattern of neutralization,
given that antibodies binding to C1-C4 domains have
been reported to compete with CD4bs broadly cross-
neutralizing antibodies for binding [47]. Moreover, Abs
specific to the C1 region have been reported to be
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cytotoxicity (ADCC) [48], which plays a role in protec-
tion from HIV infection and disease progression, as
shown also in the RV144 Thai vaccine trial [49-51].
Overall, the results of the present study highlight that tri-
meric clade A gp14094UG018 is a very effective immunogen
capable of inducing significant cross-clade humoral im-
mune responses in the rabbit model. The gp120 epitope
mapping provides potential relevant insights to clarify the
neutralization activity of the elicited immune sera confined
to Tier 1 isolates. According to these observations, possible
structural modifications of the clade A gp14094UG018 can be
envisaged (i.e. deletion of the C1 region) to improve the
breadth of the neutralization activity.
Our results provide a rationale for the design and
evaluation of immunogens to be used in HIV vaccine
strategies. In particular, clade A gp14094UG018 shows
promising characteristics for potential involvement in an
effective HIV immunization regimen.
Additional file
Additional file 1: Figure S1. Display of the regions bound in the
gp120 sequences. The conformational structure of the indicated regions
in the gp120 sequence, which are best recognized by sera from
immunized rabbits, is shown in red. Conformation of the gp120 context
as revealed by the X-ray structure (PDB code 2QAD) was used as a
prototype to identify variable and constant regions best bound by
antibodies of immunized sera [52].
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